Navigation Links
Chipscreen Biosciences and HUYA Bioscience Int'l Announce Promising Preclincial and Phase I Solid Tumor/Lymphoma Data for Chidamide/HBI-8000, New HDAC Inhibitor for Cancer
Date:10/23/2008

HDACs appear to promote tighter winding of DNA around these proteins, leading to reduced access by gene transcription factors. This results in decreased expression of proteins involved in cell differentiation, cell cycle arrest and apoptotic elimination of damaged cells -- all of which contribute to the development of cancer. HDAC inhibitors are able to restore expression of tumor suppressor genes in a highly selective manner. Treatment with HDAC inhibitors also leads, indirectly, to inhibition of the expression of angiogenesis factors, helping to choke off the blood supply to tumors.

Although significant preclinical and clinical activity has been observed with HDAC inhibitors, most have characteristics which may limit their potential for clinical success or broad applicability. In contrast, Chidamide/HBI-8000 has selectivity, potency, PK and side effect profiles that make it ideal for use as a stand-alone therapeutic, as well as in combination with a wide variety of marketed anti-tumor agents.

HUYA's Integrated Co-development Model (ICM)

The global pharmaceutical industry faces a pressing need for new untapped sources of pre-clinical and clinical stage compounds for the drug development process. HUYA was one of the first companies to recognize China's potential to help meet this need through its burgeoning biotechnology industry and world-class talent pool. HUYA has pioneered an innovative approach -- the HUYA Integrated Co-development Model -- for partnering with Chinese research institutions and pharmaceutical companies. HUYA identifies and licenses the most promising pre-clinical and clinical stage compounds in China, leverages and extends the research efforts of its Chinese partners, and provides a bridge into the Western development process and biopharma market.

Because the compounds have already been validated through a rigorous discovery, selection and development process in China, this model streamlines and accelerates developmen
'/>"/>

SOURCE HUYA Bioscience International; Chipscreen Biosciences
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
2. ImmuneRegen BioSciences, Inc. Demonstrates Radilex(TM) Increases Disease-Fighting White Blood Cells
3. Upstream Biosciences Acquires Innovative Platform Technology and Drug Candidates for Tropical Parasitic Diseases
4. Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806
5. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
6. Ardea Biosciences Lead MEK Inhibitor, RDEA119, to Enter Human Clinical Trials in Advanced Cancer Patients
7. Alacrity Biosciences Announces Positive Results from a Phase 2 Study of Its Dry Eye Treatment ALTY-0501
8. Sangamo BioSciences and Sigma-Aldrich Announce Nature Biotechnology Study Demonstrating Zinc Finger Technology for Modification of Human Stem Cells
9. Regado Biosciences Initiates Phase IIa Clinical Study of REG1 Anticoagulation System
10. Regado Biosciences Presents Positive Data From REG1 Anticoagulation System Phase Ic Study at American Heart Association 2007 Scientific Sessions
11. Regado Biosciences Presents Early Stage Clinical Data for REG1 Anticoagulation System at American Heart Association 2007 Scientific Sessions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... 2013  Omeros Corporation (NASDAQ: OMER ... Application (IND) to evaluate OMS824 in Huntington,s disease ... Drug Administration (FDA). OMS824 selectively inhibits phosphodiesterase 10 ... brain linked to a wide range of diseases ... OMS824 has shown promising results in animal models ...
(Date:5/23/2013)... -- Echo Pharma Acquisition Limited ("Royalty Pharma") announced today that ... from 90 percent to 50 percent of Maximum Elan ... the terms of the Revised Offer Document issued today, ... the terms of the Increased Offer, Royalty Pharma is ... for $12.50 per share in cash. The Increased Offer ...
(Date:5/23/2013)... Engeland, May 23, 2013 Nederland ... met lagere urinewegsymptomen geassocieerd met BPH Astellas ... dochteronderneming van Astellas Pharma Inc, gebaseerd in ... kondigde vandaag aan dat het Nederlandse College ter Beoordeling ... in Nederland. De handelsvergunning verleend voor VESOMNI ...
Breaking Medicine Technology:Investigational New Drug Application Cleared by FDA for OMS824 in Huntington's Disease 2Investigational New Drug Application Cleared by FDA for OMS824 in Huntington's Disease 3Investigational New Drug Application Cleared by FDA for OMS824 in Huntington's Disease 4Royalty Pharma Reduces Acceptance Condition to 50% Plus One Share 2Royalty Pharma Reduces Acceptance Condition to 50% Plus One Share 3Royalty Pharma Reduces Acceptance Condition to 50% Plus One Share 4Royalty Pharma Reduces Acceptance Condition to 50% Plus One Share 5Royalty Pharma Reduces Acceptance Condition to 50% Plus One Share 6Royalty Pharma Reduces Acceptance Condition to 50% Plus One Share 7Royalty Pharma Reduces Acceptance Condition to 50% Plus One Share 8Royalty Pharma Reduces Acceptance Condition to 50% Plus One Share 9Royalty Pharma Reduces Acceptance Condition to 50% Plus One Share 10Astellas ontvangt handelsvergunning voor VESOMNITM van Nederlandse College ter Beoordeling van Geneesmiddelen 2Astellas ontvangt handelsvergunning voor VESOMNITM van Nederlandse College ter Beoordeling van Geneesmiddelen 3Astellas ontvangt handelsvergunning voor VESOMNITM van Nederlandse College ter Beoordeling van Geneesmiddelen 4
(Date:5/23/2013)... May 23, 2013 A medical malpractice ... Court (reference number 110504/2009) by Lori Mandel, an office ... Ms. Mandel $8.6 million. Ms. Mandel sought the medical ... led to further complications that affected the quality of ... , The plaintiff alleged that her doctor rendered conservative ...
(Date:5/23/2013)... May 23 2013 - New techniques in imaging ... from McGill University,s Montreal Neurological Institute, and his ... from epilepsy. The combination of electroencephalogram (EEG) ... more precise localization of the areas generating epileptic ... optimal ways of intervention, if appropriate. These ...
(Date:5/23/2013)... 2013 According to a new market ... Management; Subscriber Data Management (SDM); Telecom Application Server; Service ... (2013 – 2018)", published by MarketsandMarkets, the SDP Market ... a CAGR of 9.15% from 2013 to 2018. , ... , 84 Figures , 189 ...
(Date:5/23/2013)... Miami, FL (PRWEB) May 23, 2013 In ... in 7 years. This doesn’t mean, however, that Florida’s good ... National Hurricane Center . This year, he encourages residents, it ... During hurricane season 2013, forecasters are predicting there to be ... reports WUFT . With hurricane season lasting from June ...
(Date:5/23/2013)... Worldwide Power Products (WPP), a power-generation ... has licensed the rights to sell Hythane Company's ... burn a mixture of natural gas and diesel. WPP ... for sale and rental and will also sell ... WPP's service technicians will be certified to install the ...
Breaking Medicine News(10 mins):Health News:New York Law Journal Releases Top Medical Malpractice Case for 2012: NY Supreme Court Awards $8.6 Million to Plaintiff after Doctor's Misdiagnosis Led to Personal Injury 2Health News:New York Law Journal Releases Top Medical Malpractice Case for 2012: NY Supreme Court Awards $8.6 Million to Plaintiff after Doctor's Misdiagnosis Led to Personal Injury 3Health News:New imaging techniques used to help patients suffering from epilepsy 2Health News:Service Delivery Platform (SDP) Market Is Growing at a CAGR of 9.15% & to Reach $6.94 Billion by 2018 - New Report by MarketsandMarkets 2Health News:Service Delivery Platform (SDP) Market Is Growing at a CAGR of 9.15% & to Reach $6.94 Billion by 2018 - New Report by MarketsandMarkets 3Health News:As Hurricane Season Nears, Skylake Insurance Encourages Florida Residents To Prepare Early For Safety 2Health News:Worldwide Power Products Announces Partnership with Hythane Company to Offer OptiBlend™ Bi-Fuel Solution for Diesel Engines 2Health News:Worldwide Power Products Announces Partnership with Hythane Company to Offer OptiBlend™ Bi-Fuel Solution for Diesel Engines 3
... The Health Minister Iris Evans says that Albertans are hoping for ... ,On the other hand the Albertans are known ... has prepared the initial phase of the new health care plan ... also plans to introduce more reforms by the end of the ...
... be used for regeneration of broken bones in a new ... headed by York University and // researchers from UK and ... biology, sociology and Philosophy from York University is aimed at ... the treatment of bone defects and fractures. ,Professor ...
... India as eliminated Leprosy but still we have to eradicate ... increasing the awareness regarding the // transmission of the bacteria ... disease. ,Indian Health Minister Dr. Anbumani Ramadoss during ... completely eradicate the disease which as about a 1 Lakh ...
... Doctors in New South Wales are angry at a proposal to ... Carroll, spokesman for the medical staff council at Wagga // Base ... elective surgery every fourth Friday. ,"So it'd create a ... relatively small amount of money but at great cost to patient ...
... University of Texas has revealed that moderate physical activity ... in easing depression. // Other measures adopted by ... smoking are associated with adverse health effects. ... 40 individuals, diagnosed with depression. None of the study ...
... study conducted on the prevalence of diabetes in the Indian ... has been uncovered. // So far, such studies have ... cannot be applied to South Asians. ,The research ... Diabetes Research Centre, an association of the World Health Organization ...
Cached Medicine News:Health News:Prevention And Control Of Diabetes Crucial To Indian Population 2
Used to introduce balloon, closed and non-tapered end catheters or other devices for intervention....
Used to introduce balloon, electrode, closed or non-tapered end catheters and other devices for intervention....
Used to introduce large balloon, closed and non-tapered end catheters or other devices for intervention....
Used to introduce large devices for vascular intervention....
Medicine Products: